Mike Baratta currently serves as a Scientific Director leading the Clinical Biomarker and PK mass spectrometry group at Takeda Pharmaceuticals in Cambridge, MA. He received his B.A. from Loyola University of Chicago and a Masters Certificate in Applied Healthcare Project Management from Villanova University. Mike began his career as a member of the Global Drug Metabolism group at Pharmacia/G.D. Searle and transitioned to a Principal Scientist role with Pfizer after the closure of the merger. Prior to joining Takeda in 2013, he served as a Director on Nonclinical Development, Pharmacokinetics and Biometrics with Duck Flats Pharma. Mike is a member of several FNIH biomarker consortia, industry committees and serves as a NIH/NINDS translational research grant application reviewer. Mike’s research focus is focused on analytical assay development and clinical validation of post translational biomarkers supporting patient characterization/stratification strategies.
“Unless we fully incorporate empathy for patients into our mission, we will fall short of our noble intentions”